Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 29, 2012

View Archived Issues

Novel shRNA molecule demonstrates potential efficacy for patients with mesothelioma

Enrollment commences in new phase II study of ELND-005

TAS-114 demonstrates promising antitumor activity in combination with other oncolytic agents

Selecta Biosciences and Sanofi sign global collaboration to develop allergy immunotherapies

AiCuris begins second trial of pritelivir for genital herpes

GW Pharmaceuticals identifies novel oral cannabinoid candidate for type 2 diabetes

Novel, orally bioavailable HSP 90 inhibitor developed by Taiho for cancer

Phase I and II data reveal efficacy of AMG-145

Linaclotide receives European marketing approval for IBS-C

New APE-1 inhibitors presented by U.S. Department of Health & Human Services

Usher III Initiative prepares novel compounds for Usher syndrome

Polish group designs novel agents for HCMV infection

Researchers at Merck & Co. disclose new B-raf inhibitors

APY-0201 significantly ameliorates skin inflammation in animal models of psoriasis

ElexoPharm and Merck & Co. cooperate on novel series of CYP11B2 inhibitors

FDA accepts tivozanib NDA filing

Safety and pharmacokinetic phase I data reported for MGL-3196

NovImmune begins phase I study of NI-0101

NICE recommends Bronchitol for adults with cystic fibrosis

Mochida Pharmaceutical patents new GRP40 receptor agonists

Novel heat shock protein HSP 90 inhibitor prodrugs prepared at Myrexis

NICE recommends ivabradine for patients with chronic heart failure

Coronado Biosciences begins phase I/II trial of CNDO-109

NPS licenses rights to teduglutide in Israel to Neopharm

First clinical data on RG-7212 show target modulation and signs of efficacy

Biotron begins extended preclinical toxicology studies of BIT-225

FDA committee recommends accelerated approval of bedaquiline NDA

Kowa and Sanwa Kagaku Kenkyusho set to launch Suiny in Japan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...